Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0BZBQW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | H239H-2b-K-6a-2 |
|||||
| Organization | Bio-Thera Solutions, Ltd. |
|||||
| Synonyms |
H239H-2b-K-6a-2
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISRGRSTTYS
TDTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSYYGNALDYWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAS TYRVVSVLTVLHDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISRGRSTTYS
TDTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSYYGNALDYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
DYGMH
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
YISRGRSTTYSTDTVKG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
GSYYGNALDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQRNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSAYSYPFTFGGGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQRNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSAYSYPFTFGGGTKLEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQRNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSAYSYPFTFGGGTKLEIKKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
KSSQSLLNSGNQRNYLT
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
WASTRES
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QSAYSYPFT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CN115429893A ADC14 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
93.86%
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
In the Hep-3 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | Hep-3 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
93.86%
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
In the Hep-3 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | Hep-3 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.66%
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
In the Hep-3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Hep-3 xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.66%
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
In the Hep-3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Hep-3 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
. nM
|
Negative B7H3 expression (B7H3-) | ||
| Method Description |
5000 CHO-K1 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC14 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Normal | CHO-K1 cells | CVCL_0214 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.35 nM
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 CHO-K1-B7-H3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC14 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Normal | CHO-K1-B7-H3 cells | CVCL_0214 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.35 nM
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 CHO-K1-B7-H3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC14 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Normal | CHO-K1-B7-H3 cells | CVCL_0214 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
16.32 nM
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 Calu-6 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC14 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
16.32 nM
|
Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 Calu-6 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC14 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||